€€ Satte After-Market-News: Biotech Schmiede schafft Technologiesprung €€ - 500 Beiträge pro Seite
eröffnet am 02.12.05 09:20:34 von
neuester Beitrag 02.12.05 15:11:28 von
neuester Beitrag 02.12.05 15:11:28 von
Beiträge: 25
ID: 1.023.963
ID: 1.023.963
Aufrufe heute: 0
Gesamt: 2.196
Gesamt: 2.196
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 44 Minuten | 5962 | |
| vor 29 Minuten | 4840 | |
| vor 38 Minuten | 4038 | |
| heute 15:47 | 3548 | |
| vor 27 Minuten | 2481 | |
| heute 14:53 | 1937 | |
| heute 15:18 | 1860 | |
| heute 13:07 | 1451 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.163,67 | +1,30 | 224 | |||
| 2. | 2. | 1,1300 | -18,12 | 124 | |||
| 3. | 3. | 0,1905 | +0,79 | 105 | |||
| 4. | 5. | 9,2950 | +0,54 | 64 | |||
| 5. | 4. | 171,14 | +0,56 | 55 | |||
| 6. | Neu! | 11,905 | +14,97 | 39 | |||
| 7. | Neu! | 0,4250 | -1,16 | 38 | |||
| 8. | Neu! | 4,7510 | +5,93 | 35 |
Feedback
Satte After-Market-News bei MIV Therapeutics:
MIV schafft Technologiesprung bei Kathetersystemen durch neue Polymer-freie Beschichtung. Die Weltneuheit wird jetzt erstmals auf der Messe "2005 Materials & Processes for Medical Devices Conference, on November 16 in Boston, MA" der Öffentlichkeit präsentiert.
Diese Weltneuheit ist das Ergebnis erfolgreicher Forschung bei MIV Therapeutics und wird ohne Zweifel mit einem Kurssprung belohnt werden. Daher: Strong Buy.
Kurzfristiges Kursziel: 1,24 Euro
MIV Therapeutics
WKN: 798618
NEW York: MIVT
MIV Therapeutics Premieres Research into Advanced Polymer-free Drug Delivery Systems at Leading Biomedical Conference; MIVT Premieres Revolutionary Drug Eluting System Based on its Proprietary Hydroxyapatite Coating Technologies 12/1/05
VANCOUVER, British Columbia, Dec 01, 2005 (BUSINESS WIRE) --
MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new-generation biocompatible coatings and advanced drug delivery systems, and its strategic research partner, the University of British Columbia, presented their latest achievements in research and development of a revolutionary polymer-free coatings and drug delivery systems for vascular stents and other implantable medical devices, at the 2005 Materials & Processes for Medical Devices Conference, on November 16 in Boston, MA.
At the conference, MIVT revealed to industry and scientific professionals for the first time the latest research findings into its newest, revolutionary polymer-free drug eluting technology. Most importantly, the preliminary evaluation of these potentially breakthrough coatings confirmed their exceptional suitability for drug delivery purposes and delivered extremely promising drug eluting characteristics.
MIVT is developing advanced drug-eluting coatings for stents and other devices based on the use of porous calcium phosphate, a non-polymer alternative drug-carrying vehicle designed to eliminate problems associated with current polymer-based coatings now in use. Under the Company`s research program, micro-thin films of calcium phosphates were deposited on a layer of ultra-thin Hydroxyapatite (HAp) as a vehicle for drug delivery purposes for a variety of implantable medical devices. MIVT already completed developing ultra-thin non-porous HAp coatings that have demonstrated exceptional biocompatibility and safety.
"The presentation of our newest coating and drug eluting technologies at the Boston conference gave us an opportunity for MIVT to make a decisive testimony of our achievements and capabilities before the industry`s leading scientists and professionals," said Alan Lindsay, Chairman and CEO of MIVT. "The superb biocompatibility and safety of our proprietary coatings, complemented with the extremely promising characteristics of our drug delivery solutions, are designed to directly target the weaknesses of present drug delivery technologies used in cardiovascular stents and other medical devices. We are very pleased with preliminary evaluation results of these breakthrough technologies, which have generated considerable interest and appreciation throughout our industry."
Arc Rajtar, MIVT`s Chief Technology Officer, assisted by Dr. Quanzu Yang, Ph.D., of the UBC`s Department of Materials Engineering, delivered a comprehensive presentation of MIVT proprietary coating and drug delivery technologies titled, "Hydroxyapatite Coatings for Coronary Stents." The presentation highlighted the achievements of the MIVT and UBC research teams. The Hydroxyapatite-based technologies presented at the conference included sol-gel, electro-chemical and electrophoretic methods of deposition, which resulted in ultra-thin, calcium-phosphate bio-ceramic films. Long-term evaluation of MIVT`s ultra-thin films used as a surface modification for metallic implants confirmed their exceptional biocompatibility and excellent safety during animal trials completed recently at the Methodist Hospital in Houston, TX.
MIVT`s new line of ultra-thin and drug-eluting coatings for cardiovascular stents and other medical devices utilize material called Hydroxyapatite (HAp). MIVT is developing its coating systems to target the estimated $6 billion worldwide stent market. MIVT`s coating solutions are also targeting the broader range of implantable medical devices, estimated to have the potential to grow to $100 billion or more in coming years.
"The Materials & Processes Conference gave us a unique audience to premiere our ultra-thin coating technologies for the professional community," said Mr. Rajtar. "The high-resolution electronic microscopy pictures of our polymer-free drug eluting coatings and the research results we presented were very well-received by our scientific peers and key industry representatives."
MIVT`s R&D teams are continuing to accelerate the pace of work on the Company`s breakthrough solutions. As a result of encouraging research findings, this portion of the Company`s development program is approximately 6 months ahead of schedule, Mr. Rajtar added.
About MIV Therapeutics, Inc.
MIV Therapeutics Inc. is developing a next-generation line of advanced biocompatible coatings and drug delivery systems for cardiovascular stents and for application on broad range of implantable medical devices. The Company`s ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company`s unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated superior biocompatibility and excellent safety pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company`s novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company`s drug eluting coatings are designed to suit broad range of implantable medical devices which are expected to benefit from a highly customizable drug release profile not offered by competitive solutions. MIVT`s Collaborative Research Agreement (CRA) with the University of British Columbia is supported with research and development grants from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics` Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company`s filings with the Securities and Exchange Commission including, without limitation, the Company`s recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
SOURCE: MIV Therapeutics Inc.
MIV Therapeutics Inc.
Investor Relations, 604-301-9545 x14
Toll-free: 800-221-5108
Fax: 604-301-9546
E-mail: investor@mivtherapeutics.com
Web: http://www.mivtherapeutics.com/
or, for Product Inquiries and Business Opportunities:
Arc Rajtar, 604-301-9545 Ext. 22
arajtar@mivi.ca
MIV schafft Technologiesprung bei Kathetersystemen durch neue Polymer-freie Beschichtung. Die Weltneuheit wird jetzt erstmals auf der Messe "2005 Materials & Processes for Medical Devices Conference, on November 16 in Boston, MA" der Öffentlichkeit präsentiert.
Diese Weltneuheit ist das Ergebnis erfolgreicher Forschung bei MIV Therapeutics und wird ohne Zweifel mit einem Kurssprung belohnt werden. Daher: Strong Buy.
Kurzfristiges Kursziel: 1,24 Euro
MIV Therapeutics
WKN: 798618
NEW York: MIVT
MIV Therapeutics Premieres Research into Advanced Polymer-free Drug Delivery Systems at Leading Biomedical Conference; MIVT Premieres Revolutionary Drug Eluting System Based on its Proprietary Hydroxyapatite Coating Technologies 12/1/05
VANCOUVER, British Columbia, Dec 01, 2005 (BUSINESS WIRE) --
MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new-generation biocompatible coatings and advanced drug delivery systems, and its strategic research partner, the University of British Columbia, presented their latest achievements in research and development of a revolutionary polymer-free coatings and drug delivery systems for vascular stents and other implantable medical devices, at the 2005 Materials & Processes for Medical Devices Conference, on November 16 in Boston, MA.
At the conference, MIVT revealed to industry and scientific professionals for the first time the latest research findings into its newest, revolutionary polymer-free drug eluting technology. Most importantly, the preliminary evaluation of these potentially breakthrough coatings confirmed their exceptional suitability for drug delivery purposes and delivered extremely promising drug eluting characteristics.
MIVT is developing advanced drug-eluting coatings for stents and other devices based on the use of porous calcium phosphate, a non-polymer alternative drug-carrying vehicle designed to eliminate problems associated with current polymer-based coatings now in use. Under the Company`s research program, micro-thin films of calcium phosphates were deposited on a layer of ultra-thin Hydroxyapatite (HAp) as a vehicle for drug delivery purposes for a variety of implantable medical devices. MIVT already completed developing ultra-thin non-porous HAp coatings that have demonstrated exceptional biocompatibility and safety.
"The presentation of our newest coating and drug eluting technologies at the Boston conference gave us an opportunity for MIVT to make a decisive testimony of our achievements and capabilities before the industry`s leading scientists and professionals," said Alan Lindsay, Chairman and CEO of MIVT. "The superb biocompatibility and safety of our proprietary coatings, complemented with the extremely promising characteristics of our drug delivery solutions, are designed to directly target the weaknesses of present drug delivery technologies used in cardiovascular stents and other medical devices. We are very pleased with preliminary evaluation results of these breakthrough technologies, which have generated considerable interest and appreciation throughout our industry."
Arc Rajtar, MIVT`s Chief Technology Officer, assisted by Dr. Quanzu Yang, Ph.D., of the UBC`s Department of Materials Engineering, delivered a comprehensive presentation of MIVT proprietary coating and drug delivery technologies titled, "Hydroxyapatite Coatings for Coronary Stents." The presentation highlighted the achievements of the MIVT and UBC research teams. The Hydroxyapatite-based technologies presented at the conference included sol-gel, electro-chemical and electrophoretic methods of deposition, which resulted in ultra-thin, calcium-phosphate bio-ceramic films. Long-term evaluation of MIVT`s ultra-thin films used as a surface modification for metallic implants confirmed their exceptional biocompatibility and excellent safety during animal trials completed recently at the Methodist Hospital in Houston, TX.
MIVT`s new line of ultra-thin and drug-eluting coatings for cardiovascular stents and other medical devices utilize material called Hydroxyapatite (HAp). MIVT is developing its coating systems to target the estimated $6 billion worldwide stent market. MIVT`s coating solutions are also targeting the broader range of implantable medical devices, estimated to have the potential to grow to $100 billion or more in coming years.
"The Materials & Processes Conference gave us a unique audience to premiere our ultra-thin coating technologies for the professional community," said Mr. Rajtar. "The high-resolution electronic microscopy pictures of our polymer-free drug eluting coatings and the research results we presented were very well-received by our scientific peers and key industry representatives."
MIVT`s R&D teams are continuing to accelerate the pace of work on the Company`s breakthrough solutions. As a result of encouraging research findings, this portion of the Company`s development program is approximately 6 months ahead of schedule, Mr. Rajtar added.
About MIV Therapeutics, Inc.
MIV Therapeutics Inc. is developing a next-generation line of advanced biocompatible coatings and drug delivery systems for cardiovascular stents and for application on broad range of implantable medical devices. The Company`s ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company`s unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated superior biocompatibility and excellent safety pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company`s novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company`s drug eluting coatings are designed to suit broad range of implantable medical devices which are expected to benefit from a highly customizable drug release profile not offered by competitive solutions. MIVT`s Collaborative Research Agreement (CRA) with the University of British Columbia is supported with research and development grants from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics` Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company`s filings with the Securities and Exchange Commission including, without limitation, the Company`s recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
SOURCE: MIV Therapeutics Inc.
MIV Therapeutics Inc.
Investor Relations, 604-301-9545 x14
Toll-free: 800-221-5108
Fax: 604-301-9546
E-mail: investor@mivtherapeutics.com
Web: http://www.mivtherapeutics.com/
or, for Product Inquiries and Business Opportunities:
Arc Rajtar, 604-301-9545 Ext. 22
arajtar@mivi.ca
Durch die technologische Innovation hat sich MIV ein hervorragendes Reboundpotential geschaffen.
Nachdem der Turnaround bei 1,02 € geschafft wurde sehe ich als Kursziel kurzfristig jetzt die 1,24er Widerstandlinie an. Sollte diese durchstossen werden ist der Weg frei auf 1,40 € und darüber hinaus.
Nachdem der Turnaround bei 1,02 € geschafft wurde sehe ich als Kursziel kurzfristig jetzt die 1,24er Widerstandlinie an. Sollte diese durchstossen werden ist der Weg frei auf 1,40 € und darüber hinaus.
RT FFM
1,10 Euro
ASK bei 1,12 €
Es gibt bereits erste Reaktionen auf die News. Erste Käufe aus dem ASK.
1,10 Euro
ASK bei 1,12 €
Es gibt bereits erste Reaktionen auf die News. Erste Käufe aus dem ASK.
RT jetzt schon bei 1,12 € 
ASK hoch auf 1,13 €
Denke das wir Kurse über 1,20 heute noch sehen werden. Wenn das mal reicht.
ASK hoch auf 1,13 €
Denke das wir Kurse über 1,20 heute noch sehen werden. Wenn das mal reicht.
Ich glaube die werden heute noch mächtig abgehen! 
Trading Spotlight
Die Internentseiten der Company machen einen sehr guten Eindruck! Investor Relations, Publikationen - alles tiptop.
Mit diesen neuen Nachrichten ein sehr heißer Tip!!!
Mit diesen neuen Nachrichten ein sehr heißer Tip!!!
RT schon bei 1,17 Euro !!
MIV geht gut ab heute. Denke die 1,20 werden schnell fallen. Dann sind neue Kursziele bis 1,40 angemessen.
Hab dem MOD geschrieben das der Thread in "HOT Stocks" zurückverschoben wird. Mal sehen.
MIV geht gut ab heute. Denke die 1,20 werden schnell fallen. Dann sind neue Kursziele bis 1,40 angemessen.
Hab dem MOD geschrieben das der Thread in "HOT Stocks" zurückverschoben wird. Mal sehen.
Hat jemand Kennzahlen zu der Aktie?
Umsatz, G/V, Marktkapitalisierung etc.
Umsatz, G/V, Marktkapitalisierung etc.
was mich mal interessieren würde: wie kommen die neuen damen/herren heute an die MIVT und somit hier ins board?
sind alle sehr willkommen!!! und die news ist relativ unwichtig im vergleich zu dem was noch kommen wird in 2006!
news bezieht sich nur auf ein nebenprodukt. das hauptprodukt ist 7mal umsatzstärker... d.h. die stents und deren umsatzzahlen in der "welt". wobei miv noch nicht im markt ist!
gruß,
dosco
sind alle sehr willkommen!!! und die news ist relativ unwichtig im vergleich zu dem was noch kommen wird in 2006!
news bezieht sich nur auf ein nebenprodukt. das hauptprodukt ist 7mal umsatzstärker... d.h. die stents und deren umsatzzahlen in der "welt". wobei miv noch nicht im markt ist!
gruß,
dosco
Äußerst interessant - sollte man ggf. auch long gehen!
Hab die Kennzahlen gefunden.
Sehen sehr bescheiden aus.
Sehen sehr bescheiden aus.
Kennzahlen bei einer sehr aktiven Forschungs-Company sind die wissenschaftlichen Ergebnisse!
Und da tut sich hier `ne Menge!
Und da tut sich hier `ne Menge!
[posting]19.130.882 von dosco12 am 02.12.05 10:26:25[/posting]hallo dosco !ich kann mich erinnern,dass wir beide an mivt
immer geglaubt haben.
manchmal reicht ein bisschen technisches verständnis,um hier eine wirkliche innovation zu erkennen.
mivt wird seinen weg machen,wetten?
immer geglaubt haben.
manchmal reicht ein bisschen technisches verständnis,um hier eine wirkliche innovation zu erkennen.
mivt wird seinen weg machen,wetten?
auf jeden fall!
und auch die smt sachen werden ein nettes zubrot liefern wie die heutige news zeigt.
ausserdem diversifiziert man somit in der aktie das risiko über verschiedene produkte.
das sichert den kurs nach unten ab...
ich bin very long... nein! ich bin sogar even longer!
dosco
und auch die smt sachen werden ein nettes zubrot liefern wie die heutige news zeigt.
ausserdem diversifiziert man somit in der aktie das risiko über verschiedene produkte.
das sichert den kurs nach unten ab...
ich bin very long... nein! ich bin sogar even longer!
dosco
axo: allerdings in der 911285 und somit ja auch 1:! in der miv... nur eben nviel billiger eingestiegen... (911285 = 798618)
dosco
dosco
@ dosco12
Zuviel "WIXXER" geguckt?
Sehr guter Film finde ich.
Ich denke nicht das die News nur beiläufigen Cahrakter haben. Der Zweck einer Messe ist nicht nur die Domonstration neuer Entwicklungen sondern primär die Aquise neuer Aufträge.
Vielleicht werden wir in Kürze erste Ergebnisse von der Messe zu hören bekommen. Bin da optimistisch.
Zuviel "WIXXER" geguckt?
Sehr guter Film finde ich.
Ich denke nicht das die News nur beiläufigen Cahrakter haben. Der Zweck einer Messe ist nicht nur die Domonstration neuer Entwicklungen sondern primär die Aquise neuer Aufträge.
Vielleicht werden wir in Kürze erste Ergebnisse von der Messe zu hören bekommen. Bin da optimistisch.
RT übrigens 1,17 €
Knapp 20 Kurse in 2 Stunden. Das ist schon sehr ordentlich. Denke wir werden heute noch einiges zu sehen bekommen.
Knapp 20 Kurse in 2 Stunden. Das ist schon sehr ordentlich. Denke wir werden heute noch einiges zu sehen bekommen.
Sehr lustiger Film!!!
Wenn ich das richtig sehe, befindet der Kurs sich charttechnisch an der unteren Widerstandslinie eines Trends. Kurzfristig sind 1,40 sehr realistisch!
Wenn ich das richtig sehe, befindet der Kurs sich charttechnisch an der unteren Widerstandslinie eines Trends. Kurzfristig sind 1,40 sehr realistisch!
@ Baldur
Seh ich auch so. Die Grenze bei 1 Euro hat sich als Unterstützungslinie herauskristallisiert. 3 Mal wurde 1 € angetestet und sofort durch Käufe abgewehrt.
Wie wir jetzt sehen gibt es ein schönes Rebound Momentum.
Bin gespannt wie die USA heute auf die News reagieren. Denke, dass sie gut nachziehen werden.
Seh ich auch so. Die Grenze bei 1 Euro hat sich als Unterstützungslinie herauskristallisiert. 3 Mal wurde 1 € angetestet und sofort durch Käufe abgewehrt.
Wie wir jetzt sehen gibt es ein schönes Rebound Momentum.
Bin gespannt wie die USA heute auf die News reagieren. Denke, dass sie gut nachziehen werden.
wie ist der rt? Komme da im Augenblick nicht rein?
@ Baldur
RT aktuell bei 1,17
ASK aber wieder hoch auf 1,18 Euro
RT aktuell bei 1,17
ASK aber wieder hoch auf 1,18 Euro
Hallo Leute,guckt Euch auch mal in Berlin um.Da ist noch Potenzial um die 100 Prozent!Zur Info:MIV 1.Gruss Apta
Denke MIVT wird in Berlin gar nicht gehandelt.
Nur FFM, Xetra, München und Stuttgart.
Nur FFM, Xetra, München und Stuttgart.
[posting]19.132.868 von pharma71 am 02.12.05 12:38:59[/posting]911285 - andere WKN
wie sieht es denn z.Zt. überm Teich aus, akt. Kursfeststellung ?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 224 | ||
| 124 | ||
| 105 | ||
| 64 | ||
| 55 | ||
| 39 | ||
| 38 | ||
| 35 | ||
| 27 | ||
| 26 |
| Wertpapier | Beiträge | |
|---|---|---|
| 21 | ||
| 21 | ||
| 20 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 16 |
